ERBB2 and adenocarcinoma: However, prolonged survival has been reported in patients with symptomatic bone marrow metastasis from EGFR‐ [9], ERBB2‐ mutated [15] or ALK fusion—positive [16] adenocarcinoma treated with tyrosine kinase inhibitors.